Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $31.2 million.

  • UNITED THERAPEUTICS's Change in Accured Expenses fell 5.45% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.7 million, marking a year-over-year increase of 50.80%. This contributed to the annual value of $42.7 million for FY2024, which is 25.22% down from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Change in Accured Expenses of $31.2 million as of Q3 2025, which was down 32.32% from $46.1 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Change in Accured Expenses' 5-year high stood at $46.1 million during Q2 2025, with a 5-year trough of -$34.5 million in Q4 2021.
  • In the last 3 years, UNITED THERAPEUTICS's Change in Accured Expenses had a median value of $25.8 million in 2024 and averaged $15.9 million.
  • In the last 5 years, UNITED THERAPEUTICS's Change in Accured Expenses tumbled by 422.43% in 2021 and then skyrocketed by 126.38% in 2022.
  • Over the past 5 years, UNITED THERAPEUTICS's Change in Accured Expenses (Quarterly) stood at -$34.5 million in 2021, then surged by 126.38% to $9.1 million in 2022, then slumped by 353.85% to -$23.1 million in 2023, then climbed by 22.08% to -$18.0 million in 2024, then decreased by 5.45% to $31.2 million in 2025.
  • Its last three reported values are $31.2 million in Q3 2025, $46.1 million for Q2 2025, and -$2.6 million during Q1 2025.